Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for sgen
40.24
+0.65 (1.64%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.18 - 40.43
52 week 26.02 - 52.33
Open 39.65
Vol / Avg. 755,807.00/927,201.00
Mkt cap 5.73B
P/E     -
Div/yield     -
EPS -0.91
Shares 140.17M
Beta 1.66
Inst. own 102%
Jul 28, 2016
Q2 2016 Seattle Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 8, 2016
Seattle Genetics Inc at Goldman Sachs Global Healthcare Conference - 2:20PM EDT - Add to calendar
May 24, 2016
Seattle Genetics Inc at UBS Global Healthcare Conference
May 20, 2016
Seattle Genetics Inc Annual Shareholders Meeting
May 13, 2016
Seattle Genetics Inc Annual Shareholders Meeting (Estimated)
May 11, 2016
Seattle Genetics Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
Apr 28, 2016
Q1 2016 Seattle Genetics Inc Earnings Call - Webcast
Apr 28, 2016
Q1 2016 Seattle Genetics Inc Earnings Release
Apr 13, 2016
Seattle Genetics Inc at Needham Healthcare Conference
Mar 16, 2016
Seattle Genetics Inc at Barclays Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -18.42% -35.77%
Operating margin -18.91% -35.91%
EBITD margin - -31.60%
Return on average assets -9.26% -17.80%
Return on average equity -11.99% -26.87%
Employees 759 -
CDP Score - -

Address

21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Todd E Simpson Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 53
Bio & Compensation  - Reuters
Vaughn B. Himes Executive Vice President - Technical Operations, Process Sciences
Age: 54
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 47
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 59
Bio & Compensation  - Reuters